SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Phase 3 data expected in the second half of 2024
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Arrow is the marketing partner in US
Subscribe To Our Newsletter & Stay Updated
